Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Validation and Implementation of Polygenic-Risk Prediction Models for Anthracyclines and Cisplatin in Pediatric Oncology
FY 2019-20
Summary
"Advancement in cancer therapy over the past several decades has allowed most children battling cancer today to survive beyond 5 years. With increasing survival, the lasting effects of cancer therapy are becoming a more prevalent issue. Anthracyclines and cisplatin are two widely-used drugs in the treatment of pediatric cancer, however their tendency to cause severe side-effects, or adverse drug reactions (ADRs), limits their use. Thus, efforts must be made to predict the chances that a patient will experience such an ADR prior to beginning therapy. Pharmacogenomics, the study of gene-drug interactions that influence individual variability in drug response, has allowed for identification of genetic variants associated with anthracycline-induced heart-toxicity and cisplatin-induced hearing-loss, and risk-prediction models based on these genetic variants have been developed. However, further validation of these risk-prediction models, as well as incorporation of newly discovered genetic variants improving their predictive capabilities, are needed before wide-spread implementation of pharmacogenomic testing is achieved. Therefore, I aim to evaluate the ability of these risk-models to accurately predict cases of toxicity in an independent patient cohort to demonstrate their utility and generalizability for guiding treatment decision-making. Additionally, I aim to incorporate newly discovered pharmacogenomic variants associated with anthracycline-induced cardiotoxicity and cisplatin-induced hearing-loss in order to update and refine these risk-models. Together, these objectives will serve to advance the ultimate goal of facilitating the implementation of pharmacogenomic testing into clinical practice, thus reducing ADRs and improving outcome for pediatric cancer patients."
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
429174
Name
Siemens Angela
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Validation and Implementation of Polygenic-Risk Prediction Models for Anthracyclines and Cisplatin in Pediatric Oncology
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Reactions; Oncology; Pharmacogenomics
Abstract
"Advancement in cancer therapy over the past several decades has allowed most children battling cancer today to survive beyond 5 years. With increasing survival, the lasting effects of cancer therapy are becoming a more prevalent issue. Anthracyclines and cisplatin are two widely-used drugs in the treatment of pediatric cancer, however their tendency to cause severe side-effects, or adverse drug reactions (ADRs), limits their use. Thus, efforts must be made to predict the chances that a patient will experience such an ADR prior to beginning therapy. Pharmacogenomics, the study of gene-drug interactions that influence individual variability in drug response, has allowed for identification of genetic variants associated with anthracycline-induced heart-toxicity and cisplatin-induced hearing-loss, and risk-prediction models based on these genetic variants have been developed. However, further validation of these risk-prediction models, as well as incorporation of newly discovered genetic variants improving their predictive capabilities, are needed before wide-spread implementation of pharmacogenomic testing is achieved. Therefore, I aim to evaluate the ability of these risk-models to accurately predict cases of toxicity in an independent patient cohort to demonstrate their utility and generalizability for guiding treatment decision-making. Additionally, I aim to incorporate newly discovered pharmacogenomic variants associated with anthracycline-induced cardiotoxicity and cisplatin-induced hearing-loss in order to update and refine these risk-models. Together, these objectives will serve to advance the ultimate goal of facilitating the implementation of pharmacogenomic testing into clinical practice, thus reducing ADRs and improving outcome for pediatric cancer patients."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Siemens, Angela
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~